Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Bisphosphonate treatment of lytic bone metastases
Allan Lipton, James R. Berenson
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Editorial
›
peer-review
11
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bisphosphonate treatment of lytic bone metastases'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Skeletal-related Events
100%
Bisphosphonates
100%
Survival Benefit
100%
Performance Status
100%
Bone Pain
100%
Bisphosphonate Treatment
100%
Osteoclastic Activity
100%
Lytic Bone Metastasis
100%
Tumor
50%
Multiple Myeloma
50%
Bone Metastasis
50%
Quality of Life
50%
Quality Performance
50%
Placebo Groups
50%
Placebo
50%
Phase II Study
50%
Breast Cancer
50%
Chemotherapy
50%
Osteoclast
50%
Bone Resorption
50%
Cancer Clinical Trials
50%
Potent Inhibitor
50%
Patients with Breast Cancer
50%
2-phase
50%
Clodronate
50%
Osteoclast Activation
50%
Aminobisphosphonates
50%
Lytic Bone Disease
50%
Therapeutic Benefits
50%
Analgesic Use
50%
Tumor-induced Osteolysis
50%
Delayed Deterioration
50%
Medicine and Dentistry
Bone Metastasis
100%
Bisphosphonate
100%
Pamidronic Acid
100%
Neoplasm
40%
Breast Cancer
40%
Placebo
40%
Osteolysis
40%
Bone Pain
40%
Deterioration
40%
Multiple Myeloma
20%
Quality of Life
20%
Osteoclast
20%
Bone Disease
20%
Osteoclast Activity
20%
Clodronic Acid
20%
Anodyne
20%
Pharmacology, Toxicology and Pharmaceutical Science
Bone Metastasis
100%
Bisphosphonic Acid Derivative
100%
Pamidronic Acid
100%
Breast Cancer
40%
Neoplasm
40%
Placebo
40%
Bone Pain
40%
Deterioration
40%
Multiple Myeloma
20%
Chemotherapy
20%
Bone Disease
20%
Analgesic Agent
20%
Clodronic Acid
20%
Immunology and Microbiology
Osteolysis
100%
Osteoclast Activity
50%
Multiple Myeloma
50%
Osteoclast
50%